News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Girishanthy Krishnarajah, MPH, MBA/MS, PhD

Articles by Girishanthy Krishnarajah, MPH, MBA/MS, PhD

Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy

ByGirishanthy Krishnarajah, MPH, MBA/MS, PhD,Jee-Yeon K. Lehmann, PhD,Brian Ellman, MBA,Rachel H. Bhak, MS,Maral DerSarkissian, PhD,Deane Leader, Jr, PhD, MBA,Ann L. Bullinger, PharmD,Mei

October 21st 2016

Latest Updated Articles

Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy
Published: October 21st 2016 | Updated:

Trending on AJMC

Government Shutdown Concluded but ACA Subsidies in Limbo

Can a Coffee a Day Keep AFib Away?

How Trump’s Trade Policy Could Raise Costs, Deepen Drug Shortages

FDA Approves Ziftomenib for R/R NPM1-Mutated AML

How MS Treatment Strategies Are Evolving: Rebecca Spain, MD

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.